早期乳腺癌化疗期间使用促性腺激素释放激素激动剂保护卵巢免受毒性:Anglo Celtic Group OPTION 试验
OPTION 试验是一项前瞻性随机平行组研究,评估在早期乳腺癌化疗前及化疗期间给予促性腺激素释放激素激动剂戈舍瑞林能否降低卵巢早衰风险。共随机 227 例,主要分析 202 例;戈舍瑞林组 randomization 后 12 至 24 个月闭经率为 22%,对照组为 38%(P=0.015);卵巢早衰率为 18.5% 对 34.8%(P=0.048)。结论认为戈舍瑞林降低卵巢早衰风险,在 ≤40 岁女性中尤其有效,但卵巢保护程度似乎有限。
要点
- 戈舍瑞林组 randomization 后 12 至 24 个月闭经率为 22%,对照组为 38%(P=0.015)。
- 戈舍瑞林组卵巢早衰率为 18.5%,对照组为 34.8%(P=0.048)。
- 戈舍瑞林效应在 >40 岁女性中未达统计学显著;抗苗勒管激素显示两组卵巢储备均大幅下降。
核心结论
- 本研究显示戈舍瑞林降低早期乳腺癌化疗女性的卵巢早衰风险,在 ≤40 岁女性中尤其有效。
- 卵巢保护程度似乎有限,对生育力和长期预防雌激素缺乏相关结局的临床意义尚待确定。
研究设计与样本
- 前瞻性、随机、平行组研究,在 I-IIIB 期乳腺癌化疗前及化疗期间给予促性腺激素释放激素激动剂戈舍瑞林。
- 主要结局为 randomization 后 12 至 24 个月之间的闭经,并结合卵泡刺激素浓度升高进行卵巢早衰率的附加分析。
- 共随机 227 例患者,主要分析基于 202 例患者。
主要发现
- 戈舍瑞林组 randomization 后 12 至 24 个月闭经率为 22%,对照组为 38%(P=0.015)。
- 戈舍瑞林组卵巢早衰率为 18.5%,对照组为 34.8%(P=0.048)。
- 所有接受戈舍瑞林治疗的女性在 12 个月和 24 个月时卵泡刺激素浓度均较低(分别为 P=0.027、P=0.001)。
- 戈舍瑞林效应在 >40 岁女性中未达统计学显著。
- 抗苗勒管激素评估显示两组卵巢储备在治疗期间均显著下降,中位值分别为治疗前水平的 5%(对照组)和 7%(戈舍瑞林组),组间无显著差异。
局限性
- 卵巢保护程度似乎有限。
- 对生育力和长期预防雌激素缺乏相关结局的临床意义尚待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemotherapy-induced premature ovarian insufficiency (POI) impacts fertility and other aspects of women's health. The OPTION trial tested whether administration of a gonadotropin-releasing hormone agonist during chemotherapy for early breast cancer reduced the risk of POI. PATIENTS AND METHODS: This was a prospective, randomized, parallel group study of the gonadotropin-releasing hormone agonist goserelin administered before and during chemotherapy for breast cancer with stage I-IIIB disease. The primary outcome was amenorrhoea between 12 and 24 months after randomization, supported by elevated follicle stimulating hormone concentrations to give an additional analysis as rate of POI. RESULTS: A total of 227 patients were randomized and the primary analysis was conducted on 202 patients. Goserelin reduced the prevalence of amenorrhoea between 12 and 24 months to 22% versus 38% in the control group (P = 0.015) and the prevalence of POI to 18.5% versus 34.8% in the control group (P = 0.048). Follicle stimulating hormone concentrations were also lower in all women treated with goserelin at both 12 and 24 months (P = 0.027, P = 0.001, respectively). The effect of goserelin was not statistically significant in women >40 years. Assessment of the ovarian reserve using anti-Müllerian hormone showed a marked fall in both groups during treatment to median values of 5% of pretreatment levels in the control group and 7% in the goserelin group, which were not significantly different between groups. CONCLUSION: This study shows that goserelin reduced the risk of POI in women treated with chemotherapy for early breast cancer, with particular efficacy in women aged ≤40 years old. The degree of ovarian protection also seems limited and the clinical significance for fertility and longer term prevention of estrogen deficiency-related outcomes needs to be determined.
引用
- Leonard RCF, Adamson DJA, Bertelli G, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017. PMID: 28472240. doi:10.1093/annonc/mdx184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。